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It is uncertain whether monitoring plasma ganciclovir (GCV) levels is useful in predicting cytomegalovirus (CMV) DNAemia
clearance in preemptively treated allogeneic stem cell transplant recipients. In this observational study, including 13 episodes of
CMVDNAemia treated with intravenous (i.v.) GCV or oral valganciclovir, we showed that monitoring trough plasma GCV lev-
els does not reliably predict response to therapy. Rather, immunological monitoring (pp65 and immediate-early [IE]-1-specific
gamma interferon [IFN-]-producing CD8 T cells) appeared to perform better for this purpose.
Ganciclovir (GCV) and its ester prodrug valganciclovir (V-GCV) are the first-line drugs for preemptive treatment of
active cytomegalovirus (CMV) infection in allogeneic stem cell
transplant (Allo-SCT) recipients (1). These twodrugs display sim-
ilar efficacies in CMV DNA clearance (2), despite the fact that
V-GCV leads to higher exposure than does GCV (3). Since intra-
cellular GCV triphosphate is the active form of this compound,
the plasma GCV concentration is simply a surrogate of the drug’s
antiviral activity (1, 2). Monitoring trough plasma GCV levels in
AIDS patients receiving oral GCV as maintenance therapy for
CMV retinitis was shown to be clinically useful in predicting ther-
apy failure and disease progression (4, 5). Nevertheless, no thera-
peutic concentrations of GCV have been formally defined (6). In
the solid organ transplant (SOT) setting, contradictory data have
been reported on the clinical value of routine pharmacokinetic
monitoring of GCV (6–8). This issue remains unresolved in the
Allo-SCT setting. In the current study, we monitored trough
plasma GCV levels during a number of episodes of CMVDNAemia
in order to determine whether there is a relationship between
trough plasma GCV concentrations and the efficacy in achieving
plasma CMV DNA clearance. In parallel, we prospectively enu-
merated CMV-specific (pp65 plus immediate-early [IE]-1)
gamma interferon (IFN-)-producing CD8 T cells in blood, as
previous studies demonstrated the critical influence of an ade-
quate expansion of these T-cell populations on CMV DNAemia
clearance (9, 10).
A total number of 13 episodes of CMV DNAemia developing
in 13 patients were included in the current study. None of these
patients had CMV end-organ disease. The clinical and demo-
graphic characteristics of these patients are shown in Table 1. This
study was approved by the review board and ethics committees of
the Hospital Clínico Universitario. Each patient gave written in-
formed consent to participate in the study.
Preemptive therapy with oral V-GCV (900 mg every 12 h) or
intravenous (i.v.) GCV (5 mg/kg of body weight every 12 h) was
initiatedwhen the plasmaCMVDNA load reached 500 copies/ml,
as determined by the CMV real-time PCR assay (Abbott Molecu-
lar, Des Plaines, IL, USA) (11), and interrupted upon two consec-
utive negative PCR results (12). PlasmaGCV levels weremeasured
by reverse-phase high-performance liquid chromatography
(HPLC) coupled with spectrofluorometric detection, as previ-
ously described (13). The limit of detection of the assay is 0.25
mg/liter, and the intra- and interday coefficients of variation do
not exceed 6.65%. Plasma specimens were kept at 20°C for a
maximumof 6months andwere retrieved for GCV concentration
measurements. It was shown previously that GCV remains stable
at this temperature for at least 6 months (13, 14). Blood samples
were drawn at steady state (1 day after the initiation of therapy)
just before intake of the drug (trough level). Following the current
policies at our center, blood specimens from the hospitalized pa-
tients and the outpatients were scheduled to be drawn for bio-
chemical and hematimetric analyses, virus PCR assays, and trough
cyclosporine measurements within 30 to 60 min prior to V-GCV
or i.v. GCV administration.
CMV pp65 and IE-1-specific IFN- CD8 T cells were enu-
merated by flow cytometry for intracellular cytokine staining, as
previously described (9, 10, 12). Whole blood was simultaneously
stimulated with two sets of 15-mer overlapping peptides encom-
passing the sequences of both proteins (1 g/ml/peptide). In-
creases in CMV-specific CD8 T-cell counts from baseline levels
(at the time of detection of CMV DNAemia) that reached 1
cell/l were considered significant (9, 10).
Nine out of the 13 episodes of CMVDNAemia included in the
current study were first (initial) episodes that occurred at a me-
dian of 28 days afterAllo-SCT (range, 0 to 51 days). The remaining
4 episodes were recurrences that developed at a median of 321
days after Allo-SCT (range, 144 to 766 days) (Table 2, patients 3, 9,
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10, and 13). Ten episodes were preemptively treated with i.v.
GCV, and 3 were treated with oral V-GCV. All the patients had a
glomerular filtration rate of60 ml/min.
Trough plasma GCV levels were measured in 52 specimens
(median, 3/patient; range, 2 to 10/patient). CMV-specific CD8
T-cell levels in 79 specimens were determined (median, 5/patient;
range, 2 to 13/patient). These data are shown in Table 2 and are
summarized as follows. (i) CMV DNAemia clearance was
achieved in 9 episodes, after a median of 24 days of treatment
(range, 15 to 87 days); the remaining 4 episodes were still active at
the end of the follow-up (patient death). (ii) Trough plasma GCV
levels of0.6 mg/liter were consistently measured in 10 episodes
(median, 2.90mg/liter; range, 1.17 to 5.80mg/liter). Four of these
episodes (1, 2, 4, and 5) remained unresolved at the end of the
follow-up. A significant expansion of CMV-specific IFN--pro-
ducing CD8 T cells was not demonstrated in any of these epi-
sodes. A single plasma specimen/patient from patients 1, 2, and 5
was used for sequence analysis of theUL54 andUL97 genes. These
specimens were obtained at least 4 weeks following antiviral in-
ception, and the specimens displayed CMVDNA loads of1,000
copies/ml, which is approximately the limit of detection of the
PCR sequencing method employed in the current study (9). A
mutation known to confer resistance to GCV was found only in
patient 5 (M460V in the UL97 gene). As for the 6 episodes that
were eventually cleared, a significant expansion of CMV-specific
IFN-CD8T cells was observed in 3 episodes. As for the remain-
ing 3 episodes (patients 8, 11, and 12), we cannot rule out the
possibility that functional CD8 T cells targeting other viral pro-
teins contributed to CMV DNAemia clearance. (iii) Fluctuating
trough plasmaGCV levels (defined by those changing fromhigher
than to less than 0.6 mg/liter one or more times over the study
period) were observed throughout 2 episodes. These episodes
were eventually cleared in concomitance with a significant expan-
sion of CMV-specific CD8 T cells. (iv) Undetectable plasma
TABLE 1 Demographic and clinical characteristics of study patients
Patient
no. Sexa
Age
(yr)
Underlying
diseaseb
Conditioning
regimen
HLAc
matching
Donor
type
CMV
serostatusd
Stem cell
sourcee
Acute GvHD
(grade)f
1 F 64 AML Nonmyeloablative Mismatched Related D/R PB 0–II
2 M 31 AML Myeloablative Mismatched Unrelated D/R UCB 0–II
3 F 62 AML Nonmyeloablative Matched Unrelated D/R PB 0–II
4 M 49 MM Myeloablative Mismatched Unrelated D/R UCB 0–II
5 M 39 ALL Nonmyeloablative Mismatched Unrelated D/R UCB 0–II
6 F 45 NHL Myeloablative Matched Unrelated D/R PB 0–II
7 M 63 AML Nonmyeloablative Matched Related D/R PB 0–II
8 M 27 AML Myeloablative Matched Related D/R PB III–IV
9 M 56 AML Nonmyeloablative Matched Related D/R PB 0–II
10 M 38 AA Myeloablative Mismatched Unrelated D/R UCB 0–II
11 F 58 ALL Nonmyeloablative Mismatched Unrelated D/R UCB 0–II
12 F 55 AML Nonmyeloablative Matched Related D/R PB III–IV
13 F 62 NHL Nonmyeloablative Matched Unrelated D/R PB 0–II
a F, female; M, male.
b AML, acute myeloid leukemia; MM, multiple myeloma; ALL, acute lymphocytic leukemia; NHL, non-Hodgkin’s lymphoma; AA, aplastic anemia.
c HLA, human leukocyte antigen.
d D, donor; R, recipient.
e PB, peripheral blood; UCB, umbilical cord blood.
f GvHD, graft versus host disease.
TABLE 2 Virological, immunological, and pharmacokinetic data on 13 episodes of CMV DNAemia developing in 13 allogeneic stem cell transplant
patients
Patient
no. Treatment
Trough plasma ganciclovir level
Peak CMV
DNA load
(copies/ml)
CMV DNAemia
(clearance status/day
after treatment
inception)
Significant expansion
of CMV-specific
IFN- CD8 T cellsa
Peak level of
CMV-specific
IFN- CD8
T cells (cells/l)
Median (range)
(mg/liter)
No. of
measurements
1 Ganciclovir 5.80 (0.64–5.80) 4 3,872 No/46 No 0.58
2 Ganciclovir 2.57 (1.65–4.92) 3 3,766 No/29 No 0.80
3 Ganciclovir 0.25 (0.25–1.59) 4 3,221 Yes/15 Yes 91.06
4 Ganciclovir 1.17 (1.04–3.48) 4 18,075 No/18 No 0.00
5 Ganciclovir 5.48 (1.15–53.40) 6 92,823 No/97 No 0.00
6 Valganciclovir 0.25 (0.25–6.65) 5 13,995 Yes/33 Yes 5.15
7 Ganciclovir 0.25 10 2,129 Yes/87 Yes 14.00
8 Ganciclovir 3.97 (1.54–4.61) 3 676 Yes/27 No 0.00
9 Ganciclovir 0.62–1.34 2 2,876 Yes/23 Yes 237.92
10 Ganciclovir 2.22 (1.51–2.93) 3 2,442 Yes/32 Yes 2.22
11 Valganciclovir 1.86 (1.55–2.00) 3 1,149 Yes/27 No 0.00
12 Valganciclovir 4.47–4.92 2 1,108 Yes/15 No 0.00
13 Ganciclovir 3.22 (2.75–3.69) 3 907 Yes/16 Yes 1.98
a Increases in CMV-specific CD8 T-cell counts from baseline levels (at the time of detection of CMV DNAemia) that reached1 cell/l were considered significant.
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GCV levels were seen in 1 episode, despite the administration of
i.v. GCV. This episode was eventually cleared upon a significant
expansion of CMV-specific IFN-CD8 T cells. (v) In patients 3,
9, and 13, an expansion of CMV-specific CD8T-cell levels of1
cell/l was achieved at the time of plasma CMV DNAemia clear-
ance, whereas in patients 6, 7, and 10, it preceded CMVDNAemia
clearance by 1 week (patients 6 and 10) or 3 weeks (patient 7).
Variability in the time course of reaching a sufficient T-cell expan-
sion to control active CMV infection was previously reported by
our group (10).
There is scant information on whether the measurement of
plasma GCV levels is of any clinical utility in predicting the re-
sponse to preemptive therapy in Allo-SCT recipients. In fact, the
therapeutic range of plasma GCV concentrations has not been
formally established in any clinical setting, although trough levels
between 0.2 and 2.0 mg/liter in solid organ transplant recipients
with CMV end-organ disease and 0.6 mg/liter in HIV patients
with retinitis have been tentatively proposed (4–6, 15). In this
context, we found that maintained trough plasma GCV levels
of 0.6 mg/liter were not consistently associated with CMV
DNAemia clearance. In none of the unresolved episodes was a
significant expansion of CMV-specific IFN--producing CD8 T
cells observed. These findings are in keeping with data reported by
Emery et al. (16), which revealed that an anti-CMV drug with an
efficacy of93% is required to eliminate viral growth during in-
fection of CMV-naive liver transplant recipients, whereas lower
efficacy levels (84%) are sufficient to reduce the basic reproductive
number (R0 value) to1 in experienced CMV-immune hosts. In
contrast, either undetectable or fluctuating trough plasma GCV
levels were observed throughout 4 episodes that were nevertheless
cleared, most likely at the expense of a robust expansion of CMV-
specific IFN--producing CD8 T cells of 1 cell/l, previously
shown to be associated with viral clearance (9, 10). This T-cell
expansion was manifest at the time of the first negative real-time
PCR result or shortly before it. These data further prove the crit-
ical role of CMV-specific functional T-cell immunity in control-
ling CMV replication. In addition, maintained trough levels of
0.6mg/liter were observed in 3 episodes in which a concomitant
expansion of CMV-specific IFN--producing CD8 T cells was
demonstrated, so we were unable to ascertain the relative contri-
bution of each factor to viral clearance. Taken together, our data
are in line with those of Perrottet et al. (7), who reported variable
CMV DNAemia clearance (in whole blood) despite adequate
plasma levels duringV-GCV treatment forCMVdisease in donor-
positive/recipient-negative SOT recipients.
For the current study, we used leftover plasma specimens
which were submitted to our laboratory for routine CMV DNA
load monitoring (performed once a week). Thus, we were unable
to determine the pharmacokinetic parameters, such as the maxi-
mum concentration of drug in serum (Cmax), the area under the
concentration-time curve from 0 to 12 h (AUC0–12), and the
AUC0–24, whose clinical utility in predicting response to therapy
has been proposed (6, 8, 15, 17). In addition, the unavailability of
a number of plasma specimens precluded a more systematic anal-
ysis of GCV levels throughout the duration of the episodes. De-
spite these limitations, our data indicate that monitoring trough
plasma GCV levels does not reliably predict the response to ther-
apy in this clinical setting. Rather, immunological monitoring ap-
peared to performbetter for this purpose.On the basis of our data,
prospective studies involving larger cohorts of patients on an ad-
equate sampling schedule forGCVmeasurements seem to bewar-
ranted.
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